Real-world disease burden, patient journey and treatment patterns in eosinophilic granulomatosis with polyangiitis in Europe and the USA.

Objectives: An enhanced understanding of eosinophilic granulomatosis with polyangiitis (EGPA) in clinical practice may help identify areas where patient management could be improved. The objectives of this study were to examine the real-world demographics, patient diagnostic journey, disease burden, treatment patterns, and health-related quality of life (HRQoL) of patients with EGPA. Methods: Data were drawn from the Adelphi Real World EGPA Disease Specific Programme, a cross-sectional survey of patients with EGPA and their physicians in Europe (France, Germany, Italy, Spain, and the UK) and the USA from July to December 2023. Results: The study included 121 physicians and 503 patients. Most patients were White (89%), the mean (SD) age was 49.5 (15.3) years, and the distribution of sexes was balanced. Mean (SD) time between sign/symptom onset and EGPA diagnosis was 9.8 (19.1) months. Patients had a mean (SD) of 5.5 (3.8) signs and/or symptoms at diagnosis, and physician-perceived severity of EGPA was mild in 20%, moderate in 55%, and severe in 24% of patients. Glucocorticoids were the most prescribed therapies (79%), and the use of interleukin-5-/receptor alpha-targeted therapies was low (21% mepolizumab, 7% benralizumab, <1% reslizumab). Patient-reported HRQoL and work productivity were most impacted in those with organ damage, oral glucocorticoid dose ≥10 mg/day, blood eosinophil count ≥300 cells/μL, or relapse, refractory, deteriorating, moderate, or severe disease. Conclusions: EGPA is associated with a considerable disease burden. Increased disease awareness to facilitate prompt diagnosis and treatment and optimised management to achieve remission and enhance patients' HRQoL are needed.